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with CPS type Ia (76.2%, 16/21) as compared with all other
CPS types (p <0.0001).
Seventy-nine per cent of the strains (320/401) were phe-
notypically resistant to tetracycline (MIC >8 mg/L). Among
these strains, tet(M), tet(O) and tet(L) accounted for 93.75%
(300/320), 5% (16/300), and 0.3% (1/320), respectively, and
the search for tet(M), tet(O) tet(K) and tet(L) gave negative
results for three strains (not shown). Interestingly, 14 strains
that were phenotypically susceptible to tetracycline
(MIC <8 mg/L) were tet(M)-positive.
In conclusion, this study provides the clinical and microbio-
logical characteristics of GBS strains isolated from adult inva-
sive infections in France. From these data, we show that: (i)
GBS invasive infections in adults are more frequent among
people ‡65 years of age, as described in other European and
US surveys [1–6]; (ii) CPS types Ia, III and V accounted for 72%
of all strains, a distribution similar to those observed in other
countries [1–6]; (iii) resistance to erythromycin increased
from 2007, reaching 35.24% in 2010, and was strongly associ-
ated with CPS type V; and (iv) the mef genotype was associ-
ated with CPS type Ia GBS. Continued surveillance of invasive
GBS disease in adults and genetic characterization of isolated
strains are necessary, as this might impact on strategies related
to antibiotic use and vaccine design.
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Abstract
A 24-year-old female patient developed sepsis resulting from
preoperative administration of probiotics following an aortic
valve replacement. Blood cultures revealed the causative agent
to be the probiotic Lactobacillus rhamnosus, which has recently
been implicated as an emerging aetiology of infection in those
taking probiotics. In the past few years, probiotic use in hospitals
has increased greatly. However, there is growing global evidence
that the use of probiotics in patients with organ failure, immuno-
compromised status and dysfunctional gut barrier mechanisms
can cause infections. This and other reports show the impor-
tance of establishing generally recognized safety guidelines.
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Probiotics, according to the WHO/FAO, are live microorgan-
isms that, when administered in adequate amounts, confer a
health beneﬁt on the host. Most have ‘generally recognized as
safe’ status, meaning that they are regarded as food-grade
microorganisms with no imposed health risk for consumers.
Some are members of the human ﬂora, being found in the
mouth, gastrointestinal tract and female genital tract. Because
of their safety and the possible health beneﬁts, there has been
an increase in their use worldwide. Despite these levels of
safety, there are many documented cases of various Lactobacil-
lus strains resulting in human infections [1–6]. Currently, there
are no universally accepted guidelines for the administration
of probiotics in patients with organ failure, immunocompro-
mised status and dysfunctional gut barrier mechanisms.
A 24-year-old female patient, following an aortic valve
replacement for a congenital bicuspid aortic valve, presented
in August 2009 with relapsing remitting fevers. Previous
medical history was signiﬁcant for a percutaneous aortic val-
vuloplasty for the treatment of aortic valve stenosis when
she was 11 years old. As infectious endocarditis was sus-
pected clinically in April 2009, having in mind the medical his-
tory, she was treated on an outpatient basis with empirical
antibiotics. In August of the same year, she was hospitalized
with circulatory insufﬁciency of NYHA class II, owing to sig-
niﬁcant aortic valve insufﬁciency and a previous infectious
episode. After completion of antimicrobial therapy, she
underwent aortic valve replacement surgery in August.
Perioperative antimicrobial prophylaxis was administered,
and supplementation with a probiotic preparation containing
three Lactobacillus rhamnosus strains continued for a total
period of 6 weeks during antibiotic therapy, until admission
to the cardiac surgery department.
During surgery, a 10-mm post-inﬂammatory perforation of
the valvular cusp was recognized. The affected valve was
excised, and a mechanical ATS 20-mm valve was implanted.
Cultures from the excised valve yielded negative results. How-
ever, on the ﬁrst day postoperatively, the patient presented
with high fever and other SIRS parameters. Blood samples
were collected for microbiological examination, and empirical
antimicrobial therapy was started. Two blood cultures yielded
L. rhamnosus, and the strains were collected for further analy-
sis. Following the diagnosis of L. rhamnosus sepsis, the patient
was treated promptly and recovered fully. She was discharged
from the hospital in good general health.
Analysis was performed with API 50CHL (bioMerieux,
Marcy l’Etoile, France), and cultures were sent to a probiotic
reference laboratory for molecular testing. By the use of
pulsed-ﬁeld gel electrophoresis, the two blood isolates of
L. rhamnosus (named hereafter 10330/1 and 10330/2) from
the cardiosurgical patient were compared with eight other
L. rhamnosus strains (including ﬁve strains from three probi-
otic drugs and three strains from human physiological ﬂora)
[7]. The results, including the strain designations, are shown
in Fig. 1. Genotyping of the strains conﬁrmed that
strains 10330/1 and 10330/2 had identical pulsed-ﬁeld gel
electrophoresis proﬁles to those of the L. rhamnosus strains
contained in the probiotic drug given to the patient, and
were therefore the causative agents.
The L. rhamnosus doses used as supportive therapy during
and after antibiotic therapy in this patient were those speci-
ﬁed in the probiotic product information; that is, recom-
mended doses of 1 · 1010 CFU twice daily (extra-strength
formulation, 3-mL ampoule containing powder for making a
per os suspension) or 2 · 109 CFU three times daily (normal
formulation, ampoule containing powder for making a per os
suspension). The product contains three strains of L. rhamno-
sus (40% L. rhamnosus Pen, 40% L. rhamnosus E/N, and 20%
L. rhamnosus Oxy). Indications for use include: post-antibiotic
enterocolitis with special indication for supportive therapy
for pseudomembraneous colitis; as treatment for relapsing
pseudomembraneous colitis; prevention of travellers’ diar-
rhoea; and as supportive therapy during and after antibiotic
therapy. The only contraindication is hypersensitivity to
cow’s milk protein. There are no special warnings or precau-
tions related to the use of the drug. The strains are resistant
to many antibiotics (with no MIC values listed).
Our patient was given L. rhamnosus to prevent antibiotic-
associated gastrointestinal complications, such as diarrhoea
and gastroenteritis. There are many emerging cases of
adverse events resulting from the administration of probiot-
ics, especially in hospitalized patients; these include mild
treatable conditions such as bowel distension, and more
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severe conditions such as sensitization to allergens, bactera-
emia, fungaemia, sepsis and even death [1–8]. Patients with
organ failure, severely immunocompromised patients and
patients with dysfunctional gut barrier mechanisms seem to
be at risk for adverse events related to probiotic use [1–9].
This report identiﬁes the ﬁrst known case of sepsis in a
female aortic heart valve recipient caused by probiotic
L. rhamnosus. This infection was most likely caused by bacte-
rial translocation through a weakened intestinal barrier, pos-
sibly linked with ischaemia resulting from the patient’s heart
failure. Normally, a healthy immunocompetent host would
trap and kill translocated bacteria in the mesenteric lymph
nodes. However, this mechanism was probably defective in
this patient, because of mesenteric ischaemia resulting from
heart failure impairing the gut barrier mechanism. Previous
authors have conﬁrmed that impaired intestinal barrier func-
tion may result from splanchnic ischaemia, and that the
majority of infections in humans result from mucosal trans-
mission [8,9].
In conclusion, this report highlights the potential adverse
effects of administering probiotics, such as Lactobacillus, to
patients who are presenting with organ dysfunction or fail-
ure. Although probiotics have been shown to be of beneﬁt
for the majority of patients on treatment, the risks may out-
weigh the beneﬁts in those predisposed to adverse events,
such as the immunosuppressed. To date, there is insufﬁcient
standardization of safety and administration protocols for
probiotics. We also feel that the responsibility to inform
consumers about the potential risks of probiotics for certain
categories of individuals with impaired health status should
be an integral part of the food or pharmaceutical industry.
This responsibility should be concomitant with the establish-
ment of new safety standards in this area. A revision of pro-
biotic status and warnings given with the treatment may be
required in order to encompass the potential for harm.
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FIG. 1. Typing proﬁles of lactobacilli obtained with SgsI. Electrophoretic parameters: initial pulse, 1 s; ﬁnal pulse, 25 s; voltage, 5.5 V/cm; run
time, 24 h (Molecular Analyst software). 1, Lactobacillus rhamnosus strain 10330/1 from patient; 2, L. rhamnosus strain 10330/2 from patient; 3,
L. rhamnosus Pen from drug 1; 4, L. rhamnosus E/N from drug 1; 5, L. rhamnosus Oxy from drug 1; 6, L. rhamnosus GG from drug 2; 7, L. rhamno-
sus KL53A from drug 3; 8, 9 and 10, human physiological ﬂora strains.
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